Shengxiang Ren
Tongji University(CN)Shanghai Pulmonary Hospital(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics
Most-Cited Works
- → Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study(2011)4,075 cited
- → Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer(2021)775 cited
- → Role of IL-2 in cancer immunotherapy(2016)528 cited
- → Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)(2015)464 cited
- → Tumor neoantigens: from basic research to clinical applications(2019)394 cited
- → Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer(2019)331 cited